Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

The Lancet, Journal Year: 2023, Volume and Issue: 401(10378), P. 733 - 746

Published: Feb. 7, 2023

Language: Английский

---

Small molecule inhibitors targeting the cancers

MedComm, Journal Year: 2022, Volume and Issue: 3(4)

Published: Oct. 13, 2022

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and tolerability. Small molecule inhibitors are one of the primary therapies for cancer. Due to their advantages a wide range targets, convenient medication, ability penetrate into central nervous system, many efforts have been devoted developing more small inhibitors. To date, 88 approved by United States Food Drug Administration treat cancers. Despite remarkable progress, cancer treatment still face obstacles, such as low response rate, short duration response, toxicity, biomarkers, resistance. better promote development targeting cancers, we comprehensively reviewed involved all agents pivotal drug candidates clinical trials arranged signaling pathways classification We discussed lessons learned from these agents, proper strategies overcome resistance arising different mechanisms, combination concerned Through our review, hoped provide insights perspectives research treatment.

Language: Английский

---

Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 2505 - 2505

Published: Jan. 28, 2023

Lung cancer is the deadliest worldwide. Tissue biopsy currently employed for diagnosis and molecular stratification of lung cancer. Liquid a minimally invasive approach to determine biomarkers from body fluids, such as blood, urine, sputum, saliva. Tumor cells release cfDNA, ctDNA, exosomes, miRNAs, circRNAs, CTCs, DNA methylated fragments, among others, which can be successfully used diagnosis, prognosis, prediction treatment response. Predictive are well-established managing cancer, liquid options have emerged in last few years. Currently, detecting EGFR p.(Tyr790Met) mutation plasma samples patients has been predicting response monitoring tyrosine kinase inhibitors (TKi)-treated with In addition, many efforts continue bring more sensitive technologies improve detection clinically relevant Moreover, dramatically decrease turnaround time laboratory reports, accelerating beginning improving overall survival patients. Herein, we summarized all available emerging approaches biopsy—techniques, molecules, sample type—for

Language: Английский

---

MET alterations in NSCLC—Current Perspectives and Future Challenges

Journal of Thoracic Oncology, Journal Year: 2022, Volume and Issue: 18(4), P. 419 - 435

Published: Oct. 29, 2022

Language: Английский

---

Current treatments for non-small cell lung cancer

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Aug. 11, 2022

Despite improved methods of diagnosis and the development different treatments, mortality from lung cancer remains surprisingly high. Non-small cell (NSCLC) accounts for large majority cases. Therefore, it is important to review current treatments NSCLC in clinic preclinic. In this review, we describe, as a guide clinicians, diagnostic therapies (such chemotherapy, chemoradiotherapy, targeted therapy, antiangiogenic immunotherapy, combination therapy) NSCLC.

Language: Английский

---

FOXM1: A small fox that makes more tracks for cancer progression and metastasis

Seminars in Cancer Biology, Journal Year: 2023, Volume and Issue: 92, P. 1 - 15

Published: March 22, 2023

Language: Английский

---

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer

Cancer Cell, Journal Year: 2023, Volume and Issue: 41(8), P. 1516 - 1534.e9

Published: Aug. 1, 2023

Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used treat EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by non-genetic mechanisms. Here, we define the chromatin accessibility gene regulatory signatures of sensitive resistant cell patient-derived models uncover a role for mammalian SWI/SNF remodeling complexes in TKI resistance. By profiling mSWI/SNF genome-wide localization, identify both shared cancer line-specific targets underlying state. Importantly, genetic pharmacologic disruption SMARCA4/SMARCA2 ATPases re-sensitizes subset via inhibition mSWI/SNF-mediated regulation cellular programs governing proliferation, epithelial-to-mesenchymal transition, epithelial differentiation, NRF2 signaling. These data highlight supporting suggest potential utility TKI-resistant cancers.

Language: Английский

---

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Annals of Oncology, Journal Year: 2023, Volume and Issue: 34(5), P. 468 - 476

Published: Feb. 28, 2023

Language: Английский

---

Non-small-cell lung cancer

Nature Reviews Disease Primers, Journal Year: 2024, Volume and Issue: 10(1)

Published: Sept. 26, 2024

Language: Английский

---

Oncogenic alterations in advanced NSCLC: a molecular super-highway

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Feb. 12, 2024

Lung cancer ranks among the most common cancers world-wide and is first cancer-related cause of death. The classification lung has evolved tremendously over past two decades. Today, non-small cell (NSCLC), particularly adenocarcinoma, comprises a multitude molecular oncogenic subsets that change both prognosis management disease.Since targeted alteration identified in 2004, with epidermal growth factor receptor (EGFR), there been unprecedented progress identifying targeting new alterations. Almost decades experience have allowed scientists to elucidate biological function drivers understand often overcome basis acquired resistance mechanisms. targetable alterations are approximately 60% adenocarcinoma patients Western populations 80% Asian populations. Oncogenic largely enriched non-smokers, east Asians, younger patients, though each its own patient phenotype.The current landscape druggable targets includes EGFR, anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B (BRAF), ROS proto-oncogene 1 (ROS1), Kirstin rat virus (KRAS), human 2 (HER2), c-MET (MET), neurotrophic tyrosine (NTRK), rearranged during transfection (RET), neuregulin (NRG1). In addition these known targets, others including Phosphoinositide 3-kinases (PI3K) fibroblast (FGFR) garnered significant attention subject numerous ongoing trials.In this era personalized, precision medicine, it paramount importance identify or potential patient. development therapy mirrored by diagnostic progress. Next generation sequencing offers high-throughput, speed breadth entire genomes regions DNA RNA. It for identification majority unique window into novel alterations, de novo mechanisms.In review, we discuss approach advanced NSCLC, focusing on driver through their pathophysiology, management, future perspectives. We also explore shortcomings hurdles encountered rapidly evolving field.

Language: Английский

---